Abstract
Vorinostat (Zolinza; Merck) was approved by the US FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. It is the first in a new class of anticancer agents that inhibit histone deacetylases, which have a key role in the epigenetic regulation of gene expression.
This is a preview of subscription content, log in via an institution to check access.
References
Yoo, C. B. & Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nature Rev. Drug Discov. 5, 37–50 (2006).
Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769–784 (2006).
Richon, V. M. et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA 93, 5705–5708 (1996)
Richon, V. M. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95, 3003–3007 (1998).
Yoshida, M. et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174–17179 (1990).
FDA labelling information [online], (2006).
Kelly, W. K. & Marks, P. A. Drug insight: Histone deacetylase inhibitors — development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clin. Pract. Oncol. 2, 150–157 (2005).
Richon, V. M. et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97, 10014–10019 (2000).
Duvic, M. et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic Acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 7 Sep 2006 (doi: blood-2006-06-025999v1).
Kim, E. J. et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 115, 798–812 (2005).
Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729–26734 (2005).
Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241–252 (2006).
Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673–678 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grant, S., Easley, C. & Kirkpatrick, P. Vorinostat. Nat Rev Drug Discov 6, 21–22 (2007). https://doi.org/10.1038/nrd2227
Issue Date:
DOI: https://doi.org/10.1038/nrd2227
- Springer Nature Limited
This article is cited by
-
SelSA-1, a novel HDAC inhibitor demonstrates enhanced chemotherapeutic potential by redox modulation
Scientific Reports (2023)
-
HDAC inhibitors improve CRISPR-mediated HDR editing efficiency in iPSCs
Science China Life Sciences (2021)
-
Improved identification of core biomarkers and drug repositioning for ovarian cancer: an integrated bioinformatics approach
Network Modeling Analysis in Health Informatics and Bioinformatics (2020)
-
A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells
Medical Oncology (2019)
-
Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule
Cell Death Discovery (2018)